Trial · NCT07890246
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
NCT07890246, Phase 1, Not yet recruiting, Immunome, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 1 Study of IM-1340 in Participants With Advanced Cancer. Trials, record NCT07890246. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890246
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
- NCT number
- NCT07890246
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Immunome, Inc.
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm
- Interventions
- IM-1340
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the safety and tolerability of IM-1340 in participants with advanced solid tumors | Through 30 days after last dose of study treatment; approximately 12 months | Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0, including serious adverse events, AEs of interest, AEs leading to treatment discontinuation, and deaths. |
| Secondary | Characterize the PK of IM-1340 in participants with advanced solid tumors by area under the concentration-time curve (AUC) | Through 30 days after last dose of study treatment; approximately 12 months | Pharmacokinetic (PK) parameter |
| Secondary | Characterize the PK of IM-1340 in participants with advanced solid tumors by maximum observed concentration (Cmax) | Through 30 days after last dose of study treatment; approximately 12 months | PK parameter |
| Secondary | Characterize the PK of IM-1340 in participants with advanced solid tumors by time to maximum observed concentration (Tmax) | Through 30 days after last dose of study treatment; approximately 12 months | PK parameter |
| Secondary | Characterize the PK of IM-1340 in participants with advanced solid tumors by trough concentration (Ctrough) | Through 30 days after last dose of study treatment; approximately 12 months | PK parameter |
| Secondary | Characterize the immunogenicity of IM-1340 | Through 30 days after last dose of study treatment; approximately 12 months | Incidence of antidrug antibodies (ADA) |
| Secondary | Evaluate the preliminary antitumor activity of IM-1340 in participants with advanced solid tumors | From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months | Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator |
| Secondary | Evaluate the preliminary antitumor activity of IM-1340 in participants with advanced solid tumors | From start of study until disease progression by RECIST v1.1 or initiation of subsequent anticancer therapy; up to approximately 12 months | Disease Control Rate (DCR) per RECIST v1.1 as assessed by the Investigator |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890246
GET https://conductscience.org/api/trials/v1/NCT07890246/registered